Recent advances in the discovery of small molecules targeting glioblastoma

Area of Science:

• Oncology
• Neuro-oncology
• Medicinal Chemistry

Background:

• Glioblastoma (GBM) is a highly aggressive primary brain tumor with poor prognosis.
• GBM's invasive nature and stem cell properties render surgical resection largely ineffective.
• Current treatment options, including temozolomide chemotherapy, have limited efficacy.

Purpose of the Study:

• To review recent advancements in synthetic small molecule discovery for glioblastoma.
• To identify and categorize promising anti-GBM agents developed within the last 10 years.
• To focus on compounds demonstrating significant in vitro and/or in vivo biological activity.

Main Methods:

• Systematic literature search for synthetic small molecules targeting glioblastoma.
• Inclusion of studies published within the last decade, excluding natural products.
• Analysis of compounds based on chemical class and documented biological activity.

Main Results:

• Identification of various synthetic small molecules showing potential as anti-GBM agents.
• Categorization of these compounds based on their chemical structures and drug discovery origins.
• Compilation of data on the in vitro and in vivo efficacy of the most promising candidates.

Conclusions:

• Emerging synthetic small molecules represent a promising avenue for novel glioblastoma therapeutics.
• Continued research into these compounds may lead to improved treatment strategies for GBM.
• The focus on recent, biologically active synthetic agents provides a valuable resource for future drug development.